December 16, 2025

Flipped Nivolumab/Ipilimumab Dosing Improves Responses, Survival, and Safety in Advanced Melanoma

The flipped dose for nivolumab 3 mg/kg and ipilimumab 1 mg/kg led to improved response rates and survival findings as well as lower severe immune-related toxicities compared with the standard dose of ...

The ASCO Post

November 10, 2025

Offering Ocular Aesthetics

The demand for noninvasive aesthetic treatments, such as skin rejuvenation, is on the rise in the United States. Specifically, the market size was estimated to be $20.8 billion in 2023, and it is expected to increase at a compound annual growth rate of 14.1% to 2030, according to Grand View Research.

Optometric Management

October 29, 2025

Cutaneous Squamous Cell Carcinoma: AI Model Rivals Dermatologists in Differentiation Assessment

Performance of a convolutional neural network in determining differentiation levels of cutaneous squamous cell carcinomas was on par with that of experienced dermatologists, according to the results o...

The ASCO Post

October 06, 2025

Can Nicotinamide Reduce the Risk of Skin Cancer Development?

A retrospective study aimed to determine the clinical efficacy of nicotinamide supplementation for skin cancer prevention in the general population and among solid organ transplant recipients.

The ASCO Post

October 02, 2025

RP1 Oncolytic Therapy Provides New Hope for Patients Whose Melanoma Resists Conventional Immunotherapy

About half of all patients with advanced melanoma face a poor prognosis because their cancer doesn’t respond to immunotherapy — but results of a recent clinical trial show that an unusual treatment strategy could change that.

Roswell Park Comprehensive Cancer Center

September 12, 2025

Dual-Mode Optical System Sharpens Skin Cancer Diagnosis

AI-assisted imaging merges structure and chemistry for noninvasive classification of nonmelanoma cancers

The Analytical Scientist

September 02, 2025

Use of Cemiplimab as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma

The randomized phase III C-POST trial attempted to learn whether the standard-of-care treatment in advanced cutaneous squamous cell carcinoma—cemiplimab-rwlc, which blocks the PD-1/PD-L1 pathway—could...

The ASCO Post

August 22, 2025

Perceived Dermatologic Side Effects of Cancer Treatment: Pilot Survey Findings

A recent study found that many people misunderstand how common skin, hair, and nail side effects are during cancer treatment—and those fears may lead some to avoid or delay care.

The ASCO Post

May 22, 2025

New AAP Guidelines Refresh Atopic Dermatitis Care

Applying topicals 2 to 3 times per week to previously affected areas—even when the skin appears clear—can reduce flare frequency and improve quality of life.

Conexiant